Startups vs. Giants: Who Can Break India’s Import Reliance?

India’s healthcare industry is entering a new era of scale. Hospitals are expanding, diagnostics are digitizing, and insurers are widening access. The country’s healthcare market is projected to touch USD 500 billion by 2030, yet much of its technology backbone remains imported. Nearly 70 percent of India’s medical devices-from imaging systems to surgical instruments-come from abroad. This reliance drains foreign exchange, raises treatment costs, and exposes hospitals to global supply shocks.

The question confronting policymakers and business leaders alike is: who can break this cycle? Will India’s next phase of manufacturing be led by agile startups, or by established corporate giants with scale and capital?

The Shared Challenge of Import Dependence

India’s medical industry has grown rapidly in output but remains shallow in technology depth. Thousands of firms assemble devices locally, but most rely on imported sensors, detectors, microcontrollers, and specialty polymers. High-end diagnostic, imaging, and surgical systems still arrive as fully built units.

Startups and large OEMs face the same structural barriers: limited component ecosystems, inverted duties that make finished imports cheaper, and slow, multi-layered regulatory processes. The problem is systemic, not sectoral-and solving it demands coordination across entrepreneurs, manufacturers, financiers, and the state.

Why Startups Matter

India’s startup ecosystem brings the energy and adaptability missing in legacy models. Young companies move fast, experiment often, and build products for under-served markets. Over the past few years, innovators have produced low-cost ventilators, handheld ECGs, portable ultrasound scanners, and AI-assisted pathology tools that address local realities-irregular power supply, budget limits, and environmental stress.

Startups also embrace open-source design and modular architectures, cutting time and cost. As Evaluating MedTech: Separating Signal from Noise highlights, many outperform established brands on usability and affordability.

Yet their biggest constraint is capital endurance. Clinical validation, CDSCO licensing, and CE/FDA certification can stretch for years, consuming 30–40 percent of startup funds. Public procurement cycles add uncertainty; hospitals often hesitate to trial untested local brands. Without patient capital or anchor buyers, promising innovations risk fading before commercialization.

What Giants Bring to the Table

Global majors and Indian conglomerates dominate the current market for good reasons. Companies like Wipro GE Healthcare, Siemens Healthineers, Trivitron, Meril Life Sciences, and Poly Medicare combine manufacturing discipline with regulatory experience. Their plants meet global quality standards, and their service networks cover most metros. Hospitals trust them for uptime, documentation, and compliance.

Their financial strength enables sustained R&D and multi-market certification. Many also act as regional export bases, shipping devices to Asia, Africa, and Latin America.

But as the medical devices industry in India shows, much of this activity remains assembly-led. Core design, component IP, and firmware development stay offshore. Giants optimize for global consistency, not local customization. The result: stable output but little indigenous innovation.

Why Collaboration, Not Competition, Will Win

The future of India’s MedTech ecosystem will depend less on competition and more on collaboration between startups and giants. Startups bring speed, cost innovation, and local insights; giants bring regulatory strength, scale, and credibility.

Corporate-venture programs and co-manufacturing partnerships under the Production Linked Incentive (PLI) scheme are bridging these worlds. As noted in the Invest India report^[1] shared R&D facilities are already producing radiotherapy, anaesthesia, and imaging systems that once relied entirely on imports.

This partnership model allows startups to access mentorship and patient capital while giving large players exposure to India-specific innovation. When combined with the digital healthcare transformation in India-especially the Ayushman Bharat Digital Mission-it can connect every locally made device to the national health data network, creating a seamless innovation-to-impact pipeline.

Policy as the Great Equalizer

India’s MedTech policy ecosystem is maturing quickly. The PLI Scheme and the ₹5,000 crore Promotion of Research & Innovation in Pharma–MedTech (PRIP) program encourage both component manufacturing and R&D translation. Four Medical Device Parks-in Noida, Telangana, Tamil Nadu, and Himachal Pradesh-offer common testing, metrology, and biocompatibility labs that reduce cost barriers for new entrants.

Equally important, procurement reform is moving tenders away from the lowest-price model toward total cost of ownership and uptime guarantees. This rewards reliability and lifecycle value, giving both startups and giants a clear incentive to localize design and after-sales support.

The Economic Stakes

Medical-device imports cost India USD 8–9 billion annually. But beyond currency outflow, the dependence affects supply security and hospital economics. Imported systems require foreign currency for spares, long lead times for repairs, and higher insurance coverage.

Localization flips this logic. Domestic manufacturing shortens lead times, reduces maintenance costs, and keeps IP within national boundaries. It also builds employment in high-skill engineering, machining, and quality-control roles.

According to The Case for Local Manufacturing: Economic & Clinical Value, every ₹1 invested in MedTech manufacturing generates nearly ₹3 in economic output through supply-chain linkages and service expansion.

The Clinical Stakes

Localization isn’t just about economics-it improves outcomes. Devices engineered for Indian conditions last longer and perform more consistently. Ventilators designed for high-temperature zones, imaging systems with dust-proof sensors, and analyzers with embedded self-calibration deliver higher uptime and diagnostic accuracy.

When clinicians collaborate with engineers, devices evolve faster. Firmware tweaks and field feedback loops enable continuous upgrades without waiting for overseas approvals. The result is technology that fits workflows rather than forcing hospitals to adapt to imported designs.

Such clinical agility directly affects patient experience-reducing wait times, avoiding repeat tests, and increasing trust in public-sector healthcare.

Digital Infrastructure as the Force Multiplier

Hardware innovation must now pair with data intelligence. The Ayushman Bharat Digital Mission is building national rails that connect patients, providers, and payers through unique health IDs and interoperable records.

Devices that are FHIR-compliant and ABDM-ready can plug directly into hospital networks, enabling real-time monitoring, predictive maintenance, and automated claim processing. For startups, interoperability provides instant differentiation. For giants, it ensures compliance and scalability across geographies.

In this data-driven environment, localization and digitization reinforce each other: Indian-made devices feed Indian data, which in turn guides better product design and policy decisions.

Complement, Don’t Compete

The “startups vs giants” framing oversimplifies India’s MedTech reality. The goal is not to replace one with the other but to create an integrated ecosystem where each amplifies the other’s strengths.

Startups should leverage large OEMs for certification pathways, shared labs, and global distribution. Giants should tap startups for rapid prototyping, AI analytics, and last-mile customization.

Government-backed venture funds can de-risk early-stage manufacturing R&D, while public procurement programs can serve as first customers for validated local devices. With these bridges in place, India can realistically cut import dependence to under 40 percent by 2030.

Why This Moment Matters

Global supply chains are fragmenting. Costs are rising in China, and regulatory scrutiny is tightening in the West. India has a unique window to position itself as the next MedTech manufacturing hub-not by copying others, but by designing for affordability and interoperability from day one.

The convergence of manufacturing incentives, digital infrastructure, and a vast healthcare market gives India a rare strategic advantage. Those who seize it- startups, giants, or collaborations of both- will define the country’s healthcare trajectory for the next generation.

Conclusion

India’s dependence on imported medical technology is both a vulnerability and an opportunity. The solution will not come from startups out-running giants or giants out-spending startups, but from synergy-speed meeting scale, creativity meeting capital.

As procurement becomes evidence-based and ABDM connects every node of the healthcare system, “Made in India” devices can become global benchmarks for cost, quality, and adaptability.

At GrowthJockey, we witness this convergence daily. Acting as a venture architect, we help enterprises bridge innovation and execution-using Intellsys.ai actionable insight for marketers to optimize performance and AI-driven learnings to build workforce capability. India’s journey from importer to innovator will depend on such partnerships-data-smart, design-led, and delivery-focused-turning the healthcare industry’s promise into sustainable national strength.

FAQs

Q1. Why does India depend on imported medical devices?
Limited component manufacturing, inverted duties, and lengthy approvals make importing faster and cheaper than local production.

Q2. What advantages do startups bring?
Startups innovate rapidly, design for affordability, and localize for Indian environments but struggle with long regulatory cycles and limited capital.

Q3. How do large players contribute?
Giants offer scale, capital, and compliance expertise that ensure reliability and quality assurance across India’s healthcare infrastructure.

Q4. How does government policy support localization?
PLI and PRIP schemes, along with medical-device parks and value-based tenders, reduce barriers and reward lifecycle performance over lowest price.

Q5. What benefits will patients see from localization?
Faster access to functioning equipment, lower treatment costs, and devices designed for India’s clinical and environmental realities.

1. report - Link ↑